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                       A  STUDY  OF CLINICAL PROFILE OF  OLEANDER SEED   
                                                     POISONING IN ADULTS 
 
    
             Deliberate self harm is  on the increasing trend and poisoning with yellow oleander seed  
is  common in our region. So our study  was directed to assess the clinical profile of yellow 
oleander seed poisoning in adult patients. This is a prospective study conducted at the Thanjavur 
Medical college hospital from January 2014 to August 2014. All adult patients with yellow 
oleander seed poisoning were included. 49 patients with  20 male and 29 female were admitted. 
The  mean number of seeds consumed was 4.65±2.41 . 80 % of patients had  gastrointestinal 
symptoms. Paste form is the most toxic form of ingestion, while chewed was the most common 
form consumed. ECG changes were noticed in 30 patients with sinus bradycardia being the most 
common variant. The lethal dose in our study was between 4-8 seeds. Patients who had ECG 
changes had significantly high potassium levels. There was no in hospital mortality in our study. 
Keywords: 
Yellow oleander 
Pink oleander 
Cardiac glycosides 
Digoxin  
Poisoning 
Cardiac dysrhythmias 
 
INTRODUCTION 
          Poisoning is one of the commonest way adopted  for  deliberate  self 
harm including suicidal attempts. About 800,000 people1 commit suicide 
every year world wide. Among them 17% are of Indian origin. It amounts 
to 1 lakh Indians2 committing suicide every year. 
       In the past 2 decades the suicide rate has drastically increased in 
southern and eastern states of  India. Among the southern states  
Tamilnadu and Maharashtra lead2 the list. In 2012 the suicide rate in 
Tamilnadu was 12.5% followed by Maharashtra(11%). 
         Indian government defines suicidal death3 as one if it is of  
1)unnatural cause,2)intent to die originated in the person and 3) a reason 
specified or unspecified to end his own life. 
        The most commonly involved age group as  per the 2012 national 
statistics is 15-44. Southern states were leading the suicidal  
statistics while northern states like Punjab , Uttar Pradesh had less 
incidence2. Curiously literate population were more indulging in suicides.  
Cities top the list with Chennai reporting the highest number in 2012  
(1283) followed closely by Bengaluru, Delhi3. 
        On an average, male suicide rate is twice more than female3. But the 
regional trends may vary. 
 Reasons cited2 for suicidal tendency: 
Family problems 
Illness 
Love affairs 
Sudden bankruptcy 
Failure in examinations 
Dowry dispute 
Drug abuse 
Poverty 
 Common methods adopted for suicide2: 
Poisoning (33%) 
Hanging (31%) 
Self -immolation(9%) 
according  to 2012 statistics. 
Parasuicide4: 
          Para means near or resembling . Parasuicide  is an attempted suicide 
or self harm which does not culminate in death4. The term was coined by 
Norman4. It is  a serious indicator of future suicide attempts5. This practice 
is more common in adolescents. They should be identified and given 
proper psychological counselling. 
       Females do attempt suicides more commonly but males are  three 
times more likely to die out of such attempts6.  
    Some studies have found that perfectionism might be the reason behind 
attempted suicides as those individuals  are prone to feelings of failure and 
hence depression7. 
     Now we shall see about the commonest way adopted for suicide, that is 
poisoning. 
Poison: 
       A poison is defined as a chemical substance capable of causing harm 
to living organism by chemical reaction or molecular level of action. 
         A toxin is a substance produced by living organisms for biological 
function that are harmful to other organisms. Examples are bacterial exo 
and endotoxins. 
       A venom is a toxin produced by living organisms that needs to be 
introduced by sting or bite for exhibiting its action. Examples include 
snake and scorpion venom. 
Classification of poisons: 
Broadly classified into gaseous , organic and inorganic poisons.  
Gaseous poisons include chemical warfare agents and carbon mono oxide. 
Inorganic poisons include corrosives (acids and alkalis) and metallic 
salts.(lead, mercury) 
Organic poisons include plant and animal products. They can be further 
classified  based on the systemic actions they cause. 
Local irritants- calotropis 
Neurotoxic- 
Convulsant-strychnine (nux vomica) 
Sedatives-opium and alkaloids 
Deliriant- atropica belladonna, dhatura 
Cardiotoxic – aconite, oleander, digitalis 
          So oleander plant whose all parts are poisonous is commonly grown 
everywhere . The two types of oleander plant are pink oleander and yellow 
oleander (Thevetia peruviana). 
       The yellow oleander (Thevetia  peruviana) is  a  plant  grown  for  its 
colorfulness.  It is grown commonly in tropical countries. The plant 
contains cardiac glycosides that are  poisonous  to cardiac muscle and  
produces a picture similar to digoxin  toxicity. 
                 Yellow oleander seed  poisoning is common in  Thanjavur 
region. Hence this study is meant to assess the clinical profile of  oleander  
seed  poisoning and its outcome with the management protocol followed in 
our hospital. 
 
 
 
  
AIMS AND OBJECTIVES 
 
1. To study the clinical profile of yellow oleander seed poisoning  in 
adults. 
2. To study the ECG changes in yellow oleander seed poisoning. 
3. To study the common type of arrhythmias in yellow oleander 
poisoning . 
4. To correlate the various clinical and biochemical factors with ECG 
changes. 
 
 
 
 
 
 
 
                      
 
 
 
 REVIEW OF  LITERATURE 
 
Oleander poisoning – a historical review: 
               Oleander plant is known since ancient times. It is mentioned in  
CHARAKA SAMHITA8.  The name Thevetia was  given  in honour  of  
Mr.Andre Thevit9.  He has written extensively about this plant. Yellow 
oleander  also has  alternative  names as follows  
 CEREBRA THEVETIA 
 THEVETIA NERIFOLIA 
 PILA KANER. 
    All  parts of  oleander  including  smoke from burning twigs are  toxic.   
The water in which flower is placed is also toxic.   Kernels of seeds are 8 
times more toxic than leaves followed by latex. Less toxic  parts are 
flower, bark, root and stem. 
      It had been used in the past as suicidal, homicidal poison  and criminal 
abortifacient10.  Arrows  poisoned  with  oleander extract has been used by 
American tribes for hunting.  
It has been used as cattle poison. This lethal plant has been given various 
names, KARAVIRA  and SHATA KUNDU11,12, describing its lethal 
nature when misused. 
Botany of Yellow Oleander13: 
           The two common species -   are Nerium oleander Linn 
(White or Pink oleander)  and  Yellow oleander(Thevetia  peruviana Juss). 
They  belong  to the  Apocynaceae  family13.  
Pink  oleander  is grown in  Africa and  Europe. Yellow oleander  is  
grown  in  America. Both  plants  are  grown for ornamental  purposes  in 
the  tropical  and subtropical  parts  of  the continents.  However, in some 
countries they are regarded as  weeds.  
 
Description of the plant parts: 
Pink oleander: 
       Pink   oleander (Fig. 1) is an evergreen shrub. Its leaves   are  arranged 
in a linear fashion. They appear to be leathery12.   
The leaves are dark green to yellow green in color. The   leaves  have  vein 
which is yellow in color running in the center. 
       Flowers  are always arranged in clusters.They bloom at the top of the 
twigs. The color of the flowers vary from  being white, red  and pink. The 
petals are arranged as a whorl. The number of petals is five. 
     The fruit is arranged as a narrow pod. It  has many seeds that  seem to 
be silky haired. The  sap  formed  by the plant is   
gummy and clear12. 
 
Fig 1: Pink  oleander  plant  with  flowers. 
        
Fig 2 : Yellow oleander shrub 
Yellow oleander12: 
      Yellow oleander is otherwise called as Cerebra thevetia 
or   Thevetia peruviana.  Cerebra thevetia  is a shrub mostly, and 
sometimes grows into a big tree. It is diffusely branched.  It  has dense  
crown (Fig 2). 
        Leaves appear to be glossy.   They are arranged in a linear manner. 
They are  dark  green in color12.   
    Flowering occurs in clusters. They are seen at the top of twigs. Different 
colors of flower are seen. They are yellow,peach,and orange. The flower is 
tubular. Each flower has five petals. 
     The yellow flowers are fragrant. The flowers are short lived. They are  
5-7 cm in length and  5cm  in  breadth.  Blossoms continue to appear 
throughout the year. 
 
Fig  3:  Picture shows yellow oleander flower. 
      Yellow oleander flower12(Fig 3)  is a tubular flower and has 5 petals. It 
is grown in clusters . 
Fruits: 
      Each  fruit is 4-5 cm in diameter. A single fruit has a single nut. (Fig 4 
& 5) 
 
Fig  4: Oleander  Fruits 
F 
ig 5 : Black oleander fruits 
   The fruit of yellow oleander is fleshy and triangular in shape13. Its color 
varies from green in the beginning to yellow and finally into black. 
Nuts13: 
     It is triangular or odd shaped. It has deep groove along edge. 
It is light brown in color. Each nut has two seeds. It is hard like a 
stone.(Fig.6) 
 
 
 
Seeds13: 
     It is pale yellow in color and hard like a stone (Fig.6). It has a covering  
kernel and content of glycosides. 2-5 seeds are present in single nut. Every  
part of  the oleander  plant  is poisonous to living things and even  smoke  
produced by burning the plant twigs can result in poisoning13,14.  Similarly  
intake  of  liquid  from  oleander  stem and nectar  of  flower  has  resulted  
in  toxicity of humans  and animals.   
 
Fig 6 : Oleander Nuts and seeds 
Lactiferous tissue: 
     It consists of thin walled greatly elongated much branched ducts 
containing milky fluid called latex. Lactiferous ducts are of two types. 
They are latex vessels and latex cells. They have numerous nucleus which 
lie embedded in this layer of protoplasm lining the cell which is usually 
thin and made up of cellulose13. 
Latex 
It’s a milky juice secreted by the plant. It always contains some 
waste products and it is often irritating and poisonous. It causes 
inflammation and even blister when it comes into contact with skin. The 
secretions of this latex is for defence purposes so that animals avoid such 
plants13. 
Latex composition: 
      Latex occurs as an emulsion and consisting of variety of chemical 
substances . Among the nutritive materials, sugar  
starchgrains , proteins and oils are found. The waste products in latex 
include gum, resin ,tannin  ,alkaloids ,rubber  etc. 
Latex also contains salts, enzymes and poisonous substances. 
 
 
 
Function of latex: 
      The exact function of latex is not clear perhaps in someway it is 
associated with nutrition , healing of wounds and protection against 
parasites and animals. 
Toxicology : 
          Biologically active  moieties  of  the  oleander  plants  have  been  
identified  as early as 1985 by Hayens et al15 and further  many  more  
researchers  have  validated  that   . Biologically  active  molecules  with  
in  the yellow oleander  plant   have  insecticidal  and anti-mitotic  
activity16,17 . They  show  inotropic  action  on  cardiac musculature 
(causing  increased  force  and  speed  of  contraction  of  cardiac muscle).  
The  component  molecules  of  yellow oleander  that cause cardiac   
effects  are  called the   cardiac  glycosides15,18. They contribute primarily 
to the plant’s toxicity. 
      The  cardioactive   glycosides  present   in  pink  oleander19 are  
Oleandrin,   Folinerin    and  Digitoxigenin. 
 
 
 The  glycoside content of Thevetia peruviana is : 
 Thevetin A 
 Thevetin B 
 Nerifolin 
 Thevetoxin 
 Ruvoside 
 Peruvoside 
      Cardiac glycosides in oleander, as  found  out  by Langford and 
boor10(1996)  are shown in Table 1. Karawya et al19 studied  the  various 
parts  of  the plant , common  pink  oleander.  The researchers19 found out 
that the seeds and roots of pink oleander have the maximum quantity of  
toxins . The leaves of these plants have high amounts of oleandrin.  Pink 
flower producing plants have more cardio active glycosides than  white 
flower producing  Nerium oleander. 
 
     Various studies17,20,21 done in the past have found out  that the seeds of 
the yellow oleander plant  have maximum quantity of the toxins. The  
oleander  plants  examined  by  researchers  Karawya et al  showed that the 
concentration of the toxins in the various parts differed seasonally. The 
maximum  amount was produced during flowering time. 
Table 1: Toxins in oleander10,19,20  
Nerium oleander Thevetia peruviana 
Oleandrin Thevetin  A 
Folineriin Thevetin  B 
Adynerin Thevetoxin 
Digitoxigenin Nerifoliin 
 Peruvoside 
 Ruvoside 
Flowers, seeds and roots Seeds and kernel –most 
concentrated 
 
The  cardiotonic  glycosides:  
        The  cardioactive  toxic  principles  seen in various parts  of  the  
oleander,  belong  to  a  group  of  naturally occurring  drugs  called  
cardiac  glycosides15,18,19,20. They are  naturally  obtained steroids   that 
exhibit  pharmacological  effects  on  cardiac  musculature.  The  primary  
therapeutic  significance  of  these  molecules  lies  in their  ability  to  
exhibit  a good  inotropic   effect  on  the heart.  Yet  the therapeutic  
window  of  these compounds are  narrow  and  hence toxicity  results very 
often. 
      There are  two  major  types of  cardioactive  glycosides 22  :    
 Bufadienolides   
 Cardenolides. 
Bufadienolides  are  steroid  compounds  produced  by   glands of toads23. 
Cardenolides  are  obtained from  the plants. The use of  cardenolides  
dates  back  to ancient  times. Nearly  two hundred  cardenolides have 
been identified so far.  These drugs are still in vogue with the best among 
them is digitalis10. 
       The cardenolides   identified  till  now  have a common   chemical  
structure  derived  from  three  cardiac  glycosides, Digoxin, Oleandrin  
and Thevetin-A24.  Oleandrin  is  the toxin present in  pink oleander  and  
Thevetin  A   found  in   the  yellow oleander  (Thevetia peruviana) .  
Digitoxin  is  produced  by the  foxglove  plant.  Sugar  moieties  are  
listed  by  name  only  with  the  number  of  moieties  denoted  by 
subscripts.  
        Since  the oleander cardenolides   share the similar structure  with the  
digitalis ,their actions  almost mimic the digoxin. They  resemble digitalis 
in the  form and function.  
Structure of cardiac glycoside: 
The  plant  derived  cardiac  glycosides  are  composed structurally  of  
three  distinct  subunits24 : 
 Steroid  ring 
 Lactone ring 
 Sugar moiety-Glycosidic linkage 
         The  steroid   part ,  along  with  the  lactone  ring  is  called    as  the  
‘genin’  or  ‘aglycone’ portion.   Except the carbon 10/13  functional group 
variations ,the  cardenolides  share  similar  genin  moieties  from  
compound  to  compound.   An oxygen bridge  attaches  the  carbohydrate  
moieties  to the   third  carbon  of  the  ‘A’  ring  of  the  steroid  backbone.  
Naturally  occurring  cardenolides are  usually  complex,  being  composed  
of  the  genin  with   one to four  unique monosaccharide  units.  
The  carbohydrate  in the cardenolide  decides the name for the 
particular compound (e.g.  digitoxose,  digitoxin;  thevetose, thevetin  A;  
oleandrose,  oleandrin ). It is  specific  for each compound  and thus  it 
imparts  the variability in the biological activity . The   structures  of  
digitoxin,  thevetin  A and oleandrin  are  shown in figure  (Fig.7)  for  
comparison. The  structure-activity  relationships  for  naturally  occurring  
cardenolides  are  thus   influenced  by  the  particular  carbohydrate  
moiety  and  to a  lesser  degree,  by  the  various  functional  groups  
located  at  carbon  10 and  13. 
 
Fig.7  Chemical structure  of three  cardiac  glycosides. 
  Now lets see few important points about each cardiac glycoside. To begin 
with it is the prototype cardiac glycoside “DIGOXIN”. 
 
DIGOXIN25: 
      The English botanist and chemist and physician sir William  
Withering is the first to have made publication on DIGOXIN. 
It was in the year 1785 he published his observation regarding  
the use of digoxin in congestive heart failure. 
 
Source: 
       Digoxin is a glycoside derived from digitalis purpurea (Common 
name-purple foxglove flower). Since its discovery many researchers have 
studied its potential use in congestive heart failure. The beneficial 
mechanisms include: 
1. Inhibition of plasma membrane Na+/K+ ATPase . 
2. Positive inotropic action on failing myocardium 
3. Suppression of rapid ventricular response in atrial fibrillation 
associated with heart failure. 
4. By regulating the deleterious effects associated with   sympathetic 
overactivation. 
  
Mechanism of inotropic action26: 
Normal physiology: 
    With each cardiac myocyte depolarization, Na+ and calcium ions enter 
into intracellular space through L type calcium channels. This calcium in 
turn releases  further  calcium from sarcoplasmic reticulum through  
ryanodine  receptor. Calcium interacts with myocardial contractile proteins 
increasing their contractility. During repolarisation the calcium again is 
sequesterd by Ca +ATPase in the sarcoplasmic reticulum and removed 
from cell by Na+/Ca +exchanger26,27 . 
Action of cardiac glycosides: 
     They bind and inhibit the phosphorylated alpha subunit of sarcolemmal 
Na+ / K+ ATPase and increase the intracellular sodium concentration. This 
in turn decreases the gradient for calcium exchange and as a result less 
calcium is removed from cell and more of calcium accumulation in 
sarcoplasmic reticulum. This results in increased amounts of releasable 
calcium which enhances cardiac contractility. Elevated extracellular 
potassium concentrations cause dephosphorylation  of  alpha  subunit  of  
the  Na+/K+ ATPase28,29 . 
This in turn alters the site of action of  digoxin  thereby reducing the 
drug’s binding and effect. 
Electrophysiologic actions25: 
At therapeutic concentrations : 
        It decreases automaticity of atrial and AV nodal tissues. 
Increases the maximal diastolic resting membrane potential of atrial and 
AV nodal tissues.(by increase of vagal tone and inhibition of sympathetic 
activity) .It prolongs the effective refractory period of AV node and 
reduces it conduction velocity. These actions contribute to sinus 
bradycardia, Sinus arrest, Prolongation of AV conduction ,High degree 
AV block. They also regulate  the sympathetic tone.  In patients of 
congestive cardiac failure the sympathetic activity is enhanced due to 
aberrant baroreflex response to low cardiac output. Reduced blood 
pressure reduces the baroreflex and thereby baroreflex mediated tonic 
suppression of CNS sympathetic is reduced.  
The sympathetic mediators like plasma norepinephrine and renin and 
vasopressin is elevated. The cardiac glycosides in turn favourably 
influence carotid baroreceptor mechanism. They clinically reduce the CNS 
sympathetic activity in a not well understood mechanism. 
Higher concentrations: 
     Cardiac glycosides paradoxically increase sympathetic activity  at  
higher concentrations  resulting in increased cardiac  automaticity  and 
leading to atrial and ventricular arrhythmias. Increased intracellular 
calcium load and sympathetic tone increases the spontaneous rate of 
diastolic depolarization and promotes delayed after depolarisations. These 
in turn leads to malignant  ventricular  tachy-arrhythmias. 
Pharmacokinetics: 
        Orally given digoxin is observed in proximal small intestine. The 
time to onset of effect is 30 minutes to 2 hours and the time to peak effect 
is 2 – 6 hours in case of oral digoxin. The  oral bioavailability is 60-80% 
.When IV digoxin is used 5 to 30 minutes is the time for onset of action 
and for peak effect 1 to 4 hours.  20 -30% of drug is bound to  serum 
albumin. 
        It has large volume of distribution due to extensive distribution in 
heart and kidneys. Skeletal muscle has the largest digoxin storage. The 
elimination half life ranges from 26 to 45 hours. Near steady state of drug 
is achieved 7 days of initiating drug therapy. The main route of excretion 
is renal clearance( mostly unchanged )which mainly depends on 
glomerular filtration rate. Some tubular secretion and absorption might be 
happening. Non renal excretion is 28 to 30%.(mainly biliary). The 
metabolites include dihydro-digoxin. 
Renal clearance time in renal failure patients is 3.5 – 5 days. Digoxin  
cannot be  removed by dialysis. It crosses the placenta and blood brain 
barrier. The factors influencing the pharmacokinetics and hence toxicity of 
digoxin are renal function, bioavailability of formulation, volume of 
distribution, serum albumin concentration, lean body weight, non renal 
clearance. 
       In addition drug interactions with that of amiadorone, verapamil and  
spironolactone influence the circulating digoxin level. 
Hypokalemia precipitates digoxin toxicity. Rapid infusion of 
intravenous calcium  in digitalized  patients might result in 
tachyarrhythmias. Measurement of serum digoxin is one way of assessing 
the need for dose adjustment among many other ways. 
Hemodynamic changes caused by digoxin: 
1. Increase in cardiac output 
2. Increase in left ventricular ejection fraction  
3. Decrease in pulmonary capillary wedge pressure, pulmonary artery 
pressure and systemic vascular resistance. 
4. Decrease in end systolic and end diastolic ventricular dimensions. 
ECG  changes at therapeutic doses: 
1. PR interval prolongation 
2. ST segment depression. 
Clinical use: 
       Now a days its use is limited to patients with congestive  heart failure 
with LV systolic dysfunction  in  atrial fibrillation and patients with failure 
in sinus rhythm remaining symptomatic even after maximum ACE 
inhibitor and beta blocker use. Therapeutic range -0.8 to 2ng/ml and  the  
toxic range ->2.4 ng/ml. 
      Clinical features of toxicity include GIT manifestations such as nausea, 
vomitting ,diarrhea and cardiac arrhythmias and neurological 
manifestations like xanthopsia . 
ECG changes in digoxin toxicity: 
Common: 
1. Ectopic beats of AV  junction or ventricle 
2. First degree AV  block  
3. Accelerated AV nodal rhythm. 
4. Sinus bradycardia 
5. Sinus exit arrest or block 
6. High degree AV block  
7. Ventricular arrhythmias. 
Treatment of toxicity30: 
Ectopics or first degree AV  block , accelerated  junctional rhythm 
require dosage monitoring . Lidocaine is to be used for digoxin induced 
ventricular arrhythmias. Electrical cardioversion is to be done with 
caution. Effective antidote for life threatening digoxin toxicity is anti 
digoxin immunotherapy. 
Purified Fab fragments from ovine anti-digoxin antisera are 
available and the effective neutralizing dose needs to be calculated and 
administered. 
Digi Fab dosing30: 
      40 mg of digi Fab binds 0.5 mg of digoxin. 
Dose calculation: 
   Total digoxin ingested / 0.5 mg bound per vial =number of   vials to use. 
It should be given as infusion over 15- 30 minutes after reconstitution with 
sterile water. 
Adverse effects: 
Fever, allergic reactions, serum sickness. 
Thevetin  -A31: 
       It has one methoxyl group and sugar. The  sugar content  is 
L.thevetose and two glucose. 
 
Pharmacological actions: 
       Small doses of thevetin A has stimulating effect on heart while large 
doses could depress the heart .Many studies reveal small dose of Thevetin 
increased  cardiac output and coronary blood flow. Large doses of thevetin 
reduces the blood flow. 
Effects on cardiovascular system: 
     When 1-5 cat units of  Thevetin-A is given orally it causes fall in heart 
rate. Maximal effect is seen in 2-3 hours. Thevetin A was found to be 
absorbed slowly  from gastrointestinal tract. Intravenous  infusion 
produces full effect in about 6 minutes and effect wanes in 2-3 hours31. 
        In patients of cardiac failure it improves failure by reducing venous  
pressure and by slowing heart rate. Atrial fibrillation showed improvement 
with Thevetin31. The effect of thevetin on blood pressure is equivocal. 
ECG changes: 
1. Bradycardia 
2. T-wave inversion 
3. Prolonged PR interval  
4. AV dissociation 
5. Ventricular tachycardia 
6. Ventricular fibrillation 
 Thevetin-B 
It has one methoxyl group and sugar content is L-thevetose plus two 
glucose. It has cardiotonic activities.  It has very weak digitalis like action.  
It is one of the weakest of thevetia  glycosides. ECG changes are similar to 
digitalis toxicity. 
 
 
 
Nerifolin : 
This is the major monoside of Thevetia. It  has one methoxyl unit.  
Moderately  potent cardiac glycoside having cardiotonic activities. 
Peruvoside: 
It has one methoxyl group and L- thevetose molecule. Peruvoside  
contains an aldehyde group. Peruvoside  is more prone to auto-oxidation  
in liquid form. 
Pharmacological actions: 
It is effective  by  oral  and  intravenous  route. It  is  short acting. It 
has low serum protein binding. Its  effect  on  serum  in  therapeutic  and   
toxic  doses resembles  other cardiac glycosides. It is absorbed from 
stomach and excreted by urine, feces and bile. A single dose of peruvoside 
disappeared in 72-96 hours. There is evidence for entreohepatic 
circulation. Elimination is faster than digitoxin. 
 In  normal  heart  after  a  intravenous dose it produces  
1. Increase in ejection velocity in early systole 
2. Shortening of pre-ejection period 
3. Decrease in heart rate 
4. Increase in systolic pressure with diastolic pressure remaining 
constant. 
 
Effects in congestive heart failure: 
1. Increase in cardiac index 
2. Decrease in  pulmonary arterial pressure. 
 
ECG : 
       Flattening of T waves. 
 
Indications for the use of peruvoside: 
1. Cardiac insuffiency with bradycardia  
2. Latent cardiac insuffiency  
3. Chronic cor pulmonale 
Effects of peruvoside in congestive cardiac failure: 
Parameter Effect 
Force of contraction 
Heart rate 
Cardiac output 
Right atrial pressure 
Left ventricular pressure 
 
Systolic BP 
 
Cardiac minute volume  
Peripheral vascular  
resistance 
 
Coronary blood flow 
 
Conductivity  
 
Excitability 
Powerful inotropic 
Decreases  
Increases 
Decreased 
Increase in systole and fall in 
diastole 
Increased 
 
Increases 
 
Elevated 
 
 
Augmented 
 
 
Not affected 
 
Not affected 
 
  
Advantage of peruvoside over oubain: 
      Its suitable for both oral and IV use.  It causes small alterations in 
ECG. Peruvoside has low toxicity compared to other glycosides. 
 
Ruvoside: 
    It has one methoxyl group and L-thevetose forms sugar  
moiety. 
 
Actions: 
Absorbtion range is 7 -27% from GIT and eliminated from body in 
72-96 hours. It  has strong emetic effect. Ruvoside is quick and short 
acting glycoside with cumulative toxicity. 
At low concentration by slowing heart rate it increases force of 
contraction and at high concentration it stops the heart before any inotropic 
effort is noted. 
Mechanism of toxicity: 
 Na+/k+ ATPase  inhibition: 
Demiyurek et al33  and Heard et al32 have shown that  mode of  
action  of  cardiac glycosides is by inhibition of  the    Na+/k+  
ATPase pump (Fig 7), on  the cardiac myocyte  cellular membrane.  This 
in turn,  produces a  intracellular  hypernatremia. The high intracellular 
sodium concentration affects the sodium /calcium  exchange channel and 
intracellular  hypercalcemia ensues  which leads to increased force of 
contraction. 
        The resting membrane potential  in the cell membrane  is increased  
due to  intracellular hypercalcemia, thus increase  in  spontaneous 
depolarization of the cell and hence enhanced automaticity. Lederer WJ34 
in his journal of physiology (1976) has shown that  Calcium  overload  
leads to a pulsatile  calcium release from the sarcoplasmic reticulum and  a  
fluctuation in resting membrane potential.  This fluctuation in resting  
membrane potential  produces  some thing  called  the transient inward 
current.  The transient inward current is the electrophysics  behind the  
arrhythmogenicity of the cardiac glycosides. Two thirds of this  transient 
inward current  is caused by an ionic current generated by  sodium/calcium 
exchange while the remaining current is mediated through non 
specification channels.   
 Fig 8 : Mechanism of action of  cardiac glycoside 
          Cardiac glycosides  can also produce cardiotoxic effects through  
release of inflammatory  mediators  such as histamine, nitric oxide and 
leukotrienes (Demiyurek et al33).  When the Na+/K+ pump is inhibited it 
results in hyperkalemia. This has been found out in studies of  Haynes et 
al15 . Hyperkalemia as an indicator of severeity of acute oleander 
poisoning has been shown in studies of  Bismuth et al35 . 
Autonomic nervous system: 
        Demiyurek et al33 have shown that cardiac glycosides  cause a 
profound increase in central sympathomimetic activity on heart which 
leads to arrhythmias.  
Thus  use of  atropine, or the  β-adrenergic agonists, may  therefore  result  
in  increased tachyarrhythmias . 
Role of myocarditis: 
     Yellow oleander poisoning may produce a picture of toxic myocarditis. 
It might contribute to some ECG changes. 
Role of Electrolyte imbalance:  
      Electrolyte abnormalities include hyperkalemia, which might 
contribute to ECG changes. 
Anatomic basis of ECG changes: 
       From various ECG changes we can find out the areas of conducting 
system involved. 
SA node: 
    It is commonly affected.  It manifests  as sick sinus syndrome. 
Brady type of sick sinus syndrome is most common. 
Atrio-venricular node: 
   Its involvement manifests as 
          -Junctional rhythm, 
          -Junctional tachycardia. 
 
 
Bundle of his: 
     -Right bundle-occasionally involved 
     -Left bundle-never involved 
     -Intraventricular –never involved. 
 
Myocardium: 
       Myocarditis  may occur  resulting in non specific ECG changes 
including  ST- T changes. 
Mode of poisoning: 
 Deliberate Ingestion of plant parts  
 Accidental ingestion of plant parts 
 Inhalation of smoke produced by burning the oleander    dried twigs.   
 Ingestion of herbal tea prepared from dried leaves. 
Toxic plant parts: 
            Every part of  cardiac glycosides is toxic. Even the smoke 
produced by burning plant products can induce ECG changes ,when 
inhaled. But the toxic concentration varies in the plant parts. Highest 
concentration is seen in the order, as found out by Kyerematen et al20 . 
 Seeds, 
 Leaves  
 Fruit 
 Sap.  
 
Toxic dose:  
     Ingestion of 8–10 Thevetia peruviana seeds37 can be fatal to adults. 
However the toxic dose is variable  and it depends on various factors.  The 
toxic manifestations  of  oleander seed ingestion is  determined  by  
variability in toxin concentration of seeds, crushed or non crushed seeds, 
variability in  absorption  from the intestine and inter-personal differences  
in  the cardiaovascular response.  
Time of symptom onset after ingestion: 
        It may vary as early as 2 hours to as late as 2 days. The most 
important factor that determines the rapidity in onset of action  is  the  
physical  state of the seed ingested. If  it’s ingested  in a well crushed form 
the symptoms appear  rapidly and  also more fatal. Eddleston et al39 noted 
in  two consecutive studies, that significant  cardiotoxicity  can  develop  
even  after  2 days of  seed ingestion. 
 
Clinical features38,39: 
 Gastrointestinal symptoms38,39 : 
                Oleander seeds can induce  abdominal pain, hypersalivation, 
nausea, vomiting  and diarrhea. 
Cardio vascular  changes (Rhythm disturbances-Fig 9-12) 
1. Sinus rhythm  
2. Sinus bradycardia 
3. Sinus arrest/block (pause >2 s) 
4. Mixed AV and sinus block . 
5. Nodal bradycardia  
6. Atrial fibrillation  
7. Atrial flutter with AV block  
8. Supraventricular tachycardia  
9. First-degree heart block  
10. Second-degree heart block 
11. Third-degree heart block  
12. Ventricular ectopics  
13. Nodal tachycardia 
 
 
 Fig 9: Bradycardia 
 
 
Fig 10: First degree Heart block 
13. Ventricular tachycardia 
14. Ventricular fibrillation 
 Fig 11: Ventricular fibrillation 
     Among the cardiac dysrythmias various studies have reported  Brady 
arrhythmias to be more common .In severe poisoning  ventricular  tachy-
arrhythmia  and  DC  resistant Ventricular  fibrillation has occurred. 
 
Fig 12:  T-wave flatening 
Neurological features: 
     Barceloux et al38 and Haynes et al15  observed  that oleander poisoning  
can  induce tremor, drowsiness, ataxia, visual disturbances (yellow vision), 
mydriasis, weakness, convulsions.  
They can also cause irritation of the mucus membranes, resulting in buccal 
erythema, numbness, dysesthesias and a burning sensation in mouth. 
Rare manifestations: 
Samal et al40 in his study observed jaundice and renal failure after  
Thevetia peruviana  poisoning . He subsequently reported  an additional 
four patients with jaundice and renal failure  after                   Thevetia 
peruviana  poisoning (Samal, 199040). However, jaundice and renal failure 
have not otherwise been associated with Thevetia peruviana poisoning.  
Pahwa and Chatterjee41 (1990) reported  inflammatory and degenerative 
changes in liver and kidney in an in vivo study  of  yellow oleander 
poisoning in  Rat animal model study. 
Diagnosis42: 
1. Detailed history to be recorded. 
2. Part of plant taken ,time  of  intake and  amount ingested  
3. Time of appearance of symptoms after ingestion.  However, this is 
only possible in patients who present before onset of significant  
cardiac symptoms42.  
         Patients who present to the hospital  with established cardiac  
manifestations should be given appropriate treatment for the  arrhythmias  
before the plant is identified.  Dwivedi et al43  have quoted that  in a  
geographical area where oleander is present,  a history of  poisoning 
(especially with known plant or plant product ingestion)  and  ECG 
abnormalities similar to digoxin  toxicity ,it  should  be considered 
oleander poisoning unless  proved  other-wise. 
Toxicological analysis42: 
1. Fluorescence polarization immunoassay (FPIA)44 
2. Digoxin immunoassay (Digoxin 111)45  considered to be the most 
sensitive and rapid for detecting oleander poisoning.  
3. Liquid chromatography46 -electrospray tandem mass spectrometry 
(LC-MS/MS) is  a new direct method. 
It can be used in sensitive medicolegal  cases. 
Management 42,47,48: 
      We shall review the management under the following topics: 
1. Initial assessment and supportive management 
2. Decontamination 
3. Management of arrhythmias 
4. Specific antidote 
Initial assessment and  Supportive care:  
          Airway , breathing  and  circulation  of the patient should be 
assessed  as early as possible.   This  initial management is similar  to other 
poisoning cases. If there is dehydration it should be corrected  with IV 
fluids. The consciousness of the patient  should be taken note of , as well 
his ability to protect his airways. The patient’s vitals should be monitored 
periodically. Immediately  after taking care of the basics an ECG is 
recorded and  continuous cardiac monitoring should  be initiated.  In  the 
ECG especially cardiac rhythm disturbances should be looked for . 
Duration of  monitoring: 
       Some individuals of oleander seed poisoning  with continuous  sinus 
rhythm  may suddenly  develop  cardiac arrest. The mechanism probably 
could be  the use of anticholinergic atropine excessively which can 
precipitate sudden tachyarrhythmias. 
So , for the safe discharge of a patient consider factors such  as: 
1. Absence of symptoms 
2. Normal ECG 24 hours after oleander seed ingestion 
3. Stable vital signs. 
 
In any patient of oleander seed poisoning minimum of 24 hours of  
cardiac monitoring is recommended. Severe poisoning is indicated by  
presence of 
1. Brady arrhythmias 
2. Shock 
3. Hyperkalemia 
4. Persistent vomiting  
5. Prolonged abdominal pain 
Supportive care: 
Fluid  management: 
Fluids  form the first line of management in any poisoning. 
The patients of yellow oleander poisoning may be dehydrated  
due to vomiting  most commonly and sometimes  diarrhea. 
They may develop hypotension if dehydration is very severe. 
Very vigorous rehydration should be started immediately. 
So far studies have not been conducted to decide the  type of IV fluid  to 
be used . Yet normal saline is preferred to be the best.   
Sometimes  if  vomiting  is  very  severe  the  use  of   antiemetic   like  
metachlopromide  or  ondansetron  are  warranted. 
Electrolytes  monitoring: 
Serum Potassium: 
      Hypokalemia  can  potentiate  digitalis  toxicity. Similarly  
hypokalemia can precipitate toxicity in yellow oleander Poisoning. So  
serum  potassium  levels should be checked  regularly at an interval of 6 
hours. Any hypokalemia should be corrected with IV potassium. 
Hyperkalemia: 
              Yellow oleander poisoning results in hyperkalemia similar  to  
other  cardioactive  glycosides. It is a ominous sign and leads to poor 
outcome. Hyperkalemia has to  be corrected.  
Trials  have  not  proven  that correction  of  hyperkalemia  prevents  
arrhythmias  or death.  Insulin-dextrose infusion  is  used to correct the 
hyperkalemia. Still  its  role in glycoside poisoning like yellow oleander is 
not studied. Insulin dextrose has been found to be cardioprotective in 
animal models of digoxin  toxicity. Apart from lowering the serum 
potassium level  by means of transcellular shift , the insulin dextrose 
infusion also modifies the accessibility of sodium/potassium(Na+  /K + ) 
ATPase  channels by digoxin. This action might reduce the toxicity of 
cardiac glycoside. Potassium binding resin should be avoided as the total 
body potassium is not increased . It might worsen the hypokalemia  if  
present. If renal failure or metabolic acidosis supervenes  hyper kalemia 
can be corrected with sodium bicarbonate, otherwise it is unlikely to be 
used. 
Serum Magnesium: 
     Cardiac glycoside  poisoning is an arrhythmogenic state and hence all 
electrolyte disturbances has to be taken seriously. No data is available in 
the literature  regarding serum magnesium levels  and  severity of oleander 
poisoning.  Both hypermagnesemia  and  hypomagnesemia can occur. 
Hypomagnesemia can coexist with hypokalemia and its correction is 
important as it  may precipitate  significant arrhythmias. Further 
magnesium correction will improve the potassium levels in the body.  
Serum Calcium: 
    Oleander poisoning leads to a state of intracellular  hypercalcemia  and 
so there may be a transient  intravascular i;e  extracellular  hypocalcemia. 
Usage of  IV calcium to correct thus  hypocalcemic  state  can  precipitate  
dangerous arrhythmias. 
Gastric decontamination: 
 Gastric lavage and induced vomiting48: 
      Gastric lavage has been used since time of Hippocrates for poisoning. 
Though there is no evidence in favour of gastric lavage in literature ,it is 
continued to be used in clinical practice.. 
Activated charcoal49: 
       Cardiac glycosides  gets absorbed from small intestine , metabolized 
in liver and re-secreted  in to the intestine . That again gets absorbed .Thus 
there is a enterohepatic and enterovascular cycle ,that continues till all the 
drug gets eliminated  . Logic says that interruption of this cycle may 
reduce toxicity. Hence activated charcoal  is being used to break this cycle. 
Activated charcoal  diminishes glycoside  toxicity by two mechanisms. 
1) It prevents absorption   of  glycosides   into systemic circulation  
after  ingestion. 
2)  It interrupts the entero hepatic and  enterovascular  cycles and  
hence increases the elimination. 
     In  experimental studies with animals  activated charcoal has  been 
shown to bind cardiac glycosides, thus favouring  enhanced excretion of 
the glycoside. Multi dose activated charcoal  has been found out  to  
enhance  the   elimination of cardiac glycoside. Patients with yellow 
oleander poisoning who were treated with  single dose  or  multidose 
activated charcoal in a  study trial were shown to have a less total 
hospitalization time ,due to reduced half life of the drug. There was no 
significant difference between single or multiple doses of activated 
charcoal usage. This may be explained by two mechanisms. 
1) activated charcoal acts even long after  consumption of  cardiac 
glycoside  by interfering with the notorious enterohepatic and 
enterovascular cycling. 
  2) atropine  given concomitantly in these patients  delays  the 
gastrointestinal transit time and  SDAC  had more time to adsorb the 
glycoside. 
      It’s a double edged sword and at times delayed gastrointestinal transit 
time might backfire as more time is available for glycoside absorption    
and hence increased toxicity.  So many studies  have been conducted to 
study whether SDAC or MDAC is effective. It is difficult to have a final 
say whether SDAC or MDAC is efficacious.  In clincal  practice single  
dose activated charcoal is being used widely49,50. More studies are needed 
to establish the superiority of MDAC if any. 
Management of  Rhythm disturbances51: 
        Bradyarrthymias51  are  the most commonly encountered  rhythm 
disturbance in oleander poisoning. They are the most important  primary 
cause  of  death in yellow oleander  poisoning. They are commonly treated 
with  
1) Atropine, 
2) Isoprenaline 
3) Temporary pacemaker  insertion .    
Ideally all  symptomatic  bradyarrhythmias  should receive a 
temporary pacemaker.  However in  rural areas with out  tertiary care 
facilities , pacing may not be available and hence pharmacotherapy is 
considered.  Beta-adrenergic agonists or anticholinergics  are used 
commonly in this setups. The benefit of  treating   asymptomatic 
bradyarrhythmias  with these drugs is not proven. 
  This may be a double edged sword.  Increasing  the  heart rate 
results  in  elevated  intracellular  calcium  concentrations. Elevated 
intracellular calcium   precipitates  abnormal electrical activity, like  early 
and delayed  after depolarizations. 
The aberrant electrical activity can precipitate ventricular 
fibrillation. 
             Glycoside increases intracellular Ca2+ concentration. Beta-
adrenergic stimulation increases peak systolic intracellular Ca2+ 
concentrations .   Isoprenaline is one of the common beta-agonist used to 
treat the bradycardia in oleander poisoning.  
           Theoritically speaking  isoprenaline  can  itself  precipitate  
tachyarrhythmias. Despite  the  regular  use of  isoprenaline  in clinical  
practice to treat brady arrhythmias  its  safety and efficacy is not known. 
 Few words about isoprenaline: 
 Isoprenaline is a strong beta 1 and beta 2 adrenergic agonist. It has a half 
life of 3-7 hours. It is metabolised by liver and lungs and excreted in the 
urine 50-80% 
 Dose: can be given as bolus dose or continuous infusion. 
Bolus dose: 
 Initially if IV bolus is used it is given  at the dose of 0.02-0.06mg 
followed by 0.01-0.02mg . 
Infusion dose : 
5 microgram per minute followed by doses of 2-20microgrm minute based 
on patients response. 
Common adverse effects encountered are tachycardia, hypertension, 
dysrhythmia, confusion, tremor, headache, angina and syncope. 
Another drug  used  commonly  to increase the  heart  rate is  
atropine. It  improves  atrioventricular  nodal conduction. The  effects of 
atropine  are short-lived .So  repeated doses or infusion of atropine  may 
be required. The beneficial role of atropine  in reducing mortality or 
decreasing the need of temporary pace maker insertion  is not  proven in 
scientific trials. 
Atropine  is anticholinergic and  hence it also reduces 
gastrointestinal  motility  causing  a state of ileus.  This can increase  the  
time  available for absorption of cardiac glycosides . So atropine may  also 
paradoxically  increase the toxicity of oleander  glycosides. Hence   
atropine  has to be with held  when  features  of  atropine  toxicity  like 
restlessness, confusion, blurred vision, tachycardia, hypertension  occur . 
Large doses of atropine can increase the  myocardial workload, due 
to increase in heart rate. This  may result in a further rise in intracellular 
calcium concentrations (as in the case of isoprenaline) and  precipitate  
dangerous tachyarrhythmias, including ventricular fibrillation .  
 But  these effects are least likely  if low doses of atropine alone are 
used. Careful  dosing and small increments of atropine may prevent 
tachyarrhythmias.  In patients of yellow oleander poisoning the incidence 
rate of atropine toxicity causing tachyarrhythmia  is not known. The  target  
heart  rate  when using  atropine  should be  between 60 and 90 beats per 
minute. 
Few words about atropine perse: 
Atropine is a muscarinic receptor antagonist. It has a half life of 
about 2- 3 hours.   
It is metabolized in the liver and excreted in the urine. 
For sinus bradycardia the dose is 0.5 to 1 mg or 0.04 mg /kg every 5 
minutes not to exceed 3 mg. 
Commonly observed adverse effects include palpitations , dry 
mouth, dry skin , difficulty in micturition , restlessness and confusion. 
Cardiac pacing51  
      Temporary  pacemaker insertion is the  common method  of treatment 
if the heart rate of the patient is below  40/min  with any form of sick sinus 
syndrome or heart block .  
      Though  there are no randomized control trials,  in setting of oleander  
poisoning ,temporary pacing should be offered to all patients with heart 
rate  < 40/min.  
      Temporary  cardiac  pacing should be continued till the  rhythm returns 
to normal . However pacing is not available  every-where and  adequate 
training  is important  in  pacemaker insertion ,as  following complications 
can occur 
1. Local trauma,  
2. Pneumothorax,  
3. Bleeding, and 
4. cardiac perforation-very rare 
   The much feared complication associated with pacemaker insertion is  
the development of tachyarrhytmias  due to stimulation  of irritable  
myocardium directly by the pacing wire. 
Tachyarrhythmias52,53: 
        The  most  dreaded   rhythm   disturbance  in  yellow oleander 
poisoning  is  tachyarrhythmias  .  They are resistant to  usual treatment 
methods. Research  studies are not available regarding the use of  
antiarrhythmic agents in oleander poisoning . Whatever scientific  data  
available is from digitalis poisoning. Lidocaine  is the preferred agent in 
the treatment of ventricular arrhythmias. 
      Lidocaine 100 mg is administered intravenously(50 mg if circulation is 
impaired), followed by 4 mg/min for 30 min, 2 mg/min for 2 h, then 1 
mg/min). Other  antiarrhythmic agents like  Amiodarone, quinidine, and 
calcium-channel blockers  are  contraindicated  as they may increase 
digitalis concentrations. The use of  beta-blockers may worsen heart block. 
        Ventricular tachycardia seen in oleander poisoning  is often resistant 
to  treatment with electrical cardioversion. Electrical cardioversion is to be 
avoided as it  can also result in ventricular fibrillation or asystole. It 
possibly has a role in resistant ventricular tachycardia  cases using lower 
energy.  
Atrial  fibrillation associated with digitalis toxicity shows a slow  
ventricular response . It requires no specific management. 
Role of intravenous magnesium: 
  Normally   magnesium   is    required  for  Na+/K+  pump 
functioning. Hence it opposes the action of digoxin. So intravenous  
magnesium   can be considered   in case of cardiac glycoside poisoning  
even in the presence of hypermagnesemia or normomagnesemia.  More 
studies are required to prove its efficacy.  
    
 
 
The specific antidote: 
Digoxin specific antibody fragments: 
       In management of  any poisoning   the use of specific antidote plays a 
crucial role. Digoxin  specific antibody fragments54,55  are the specific 
antidote in oleander poisoning. . Various  studies have  confirmed it to be 
effectively reverting dangerous arrhythmias  and  hyperkalemia. 
    It  is likely that a reduction in cardiac arrhythmias will result in a 
reduced mortality. A single observational clinical study done in Srilanka 
has shown reduced mortality with the use of this specific antidote. 
       The effective dose of digoxin specific  antibody fragment , is 1,200 
mg intravenously,  irrespective of age, sex, or body weight.  
      The use of smaller doses over longer period  has not been proven to be 
effective than usual dose in trials. The dose needed in yellow oleander 
poisoning   is significantly higher than that in digoxin poisoning. 
     Digoxin specific antibody fragment is very  expensive.  A single dose 
(1,200 mg) of digoxin-specific antibody fragments is dissolved in 100 ml 
of normal saline and given by intravenous infusion over 20 min. The ideal 
dosing regimen is yet to be  formulated  through various studies and trials.. 
Side effect is uncommon, and a test dose is not needed. 
One should be alert and watchful for the development of anaphylactic 
reactions. Yet prophylactic use of antihistamine or steroid is not needed. In 
the event  of anaphylactic reactions, the infusion has to  be stopped 
immediately  and the standard management protocol for anaphylaxis has to 
be followed.  
In some  non-responsive patients, a second or rarely a third dose of 
digoxin-Specific antibody might be needed. 
 
Other measures: 
     Hemodialysis or hemoperfusion have  not been found  to be effective  
in cardiac glycoside poisoning because of the large volume of distribution. 
Yet studies have not been done studying their role  in yellow oleander 
poisoning.  
 
Role of oleander as medicine: 
          Charakas, a pioneer in Ayurvedic medicine and Sushrutha an 
ancient surgeon have made references about this plant in their treatises. 
According to the literature, oleander has been used as medicinal plant to 
treat various diseases in Indian system of medicine. 
Role in Ayurveda : 
To treat  Dropsy  
              Rheumatism 
              Skin infections 
              Anal fissure and hemorrhoids 
              Ureteric stone 
              Malaria 
Role in Unani: 
To treat skin lesions of 
                Leprosy  
               Syphilis. 
It has been used as an abortifacient too. 
                       
MATERIALS AND METHODS 
Study design: 
     This study is a single centre  non randomized prospective study meant 
to study the clinical profile of yellow oleander seed poisoning. 
Study period: 
     Consecutive patients of yellow oleander seed poisoning admitted in 
Thanjavur medical college hospital during the period of  8 months between  
January 2014  to August 2014 were taken up for the study. 
Inclusion criteria: 
    All adult patients of yellow oleander seed poisoning aged above 18. 
Exclusion criteria: 
     1)Pediatric  patients 
     2) Patients who had coexisting cardiac illness 
3) Patients who were taking cardiotoxic drugs 
4) Patients who had ingested plant parts other than seed. 
5) Patients who were known cases of dyselectrolytemias  
 Study centre 
      This study was carried out in Department of Medicine, Thanjavur 
medical college hospital, Thanjavur, Tamilnadu. 
All cases were admitted  and  examined in detail in the wards and  
clinical  data was recorded in the proforma  annexed  herein. All cases 
were followed till discharge or death. 
Clinical details: 
Personal particulars like age , sex and socio-demographic details 
were obtained. Clinical details regarding the poisoning such as color of the 
seed , number of seed , form of consumption, taken in empty stomach or 
with food were enquired and recorded. Time interval between poisoning 
and hospitalization and details of first aid were obtained . Clinical 
symptoms experienced by the patients were recorded. 
Clinical examination: 
    Examination was done in a detailed manner and vital signs were 
recorded and system examination was carried out. 
 
 ECG Monitoring : 
    ECG was taken in all cases after admission. Routine conventional limb 
leads ,chest leads and long strips were recorded. Continuous  cardiac 
monitoring was done in the first 24 hour period and thereafter in some 
needful patients. After that ECG was recorded twice  for the second day 
and thereafter once daily until discharge. 
Lab investigations: 
1. Random blood sugar 
2. Blood urea  
3. Serum creatinine 
4. Serum potassium 
5. Serum sodium  
6. Urine routine 
     These investigations  were carried out in all patients. 
Echocardiogram : It was carried out in all patients who were included in 
the study. 
Treatment : 
    All patients were admitted and initially treated with  gastric lavage with 
normal saline. They were treated with IV fluids and steroid . If sinus 
bradycardia was there orciprenaline was started and given until the 
bradycardia resolved.  If there was severe bradycardia with heart rate <40 
the patients were kept in ICU and treated with small doses of atropine.  
Pacing facilities as well as digoxin specific antibodies are not available in 
our hospital. 
             
 
 
 
 
 
 
 
 
                                 
 
 
 
 
 
                                                          STATISTICAL ANALYSIS 
 
           The   patients  data  were collected  prospectively and entered in  
the proforma (Annexure). The data was digitalised  in Microsoft  excel 
software . Statistical analysis was done using SPSS 20 software.        
          The categorical variables have been described as proportions and 
percentages. The continuous variables have been expressed as Mean and 
Standard deviation, as well as range. 
     The effect of various factors on presence of  ECG changes and no 
ECG changes was  analysed  by unpaired ‘t’test (difference between 
means)  for continuous data. Chi-square test and Fischer’s exact test 
(difference between proportions)  have been used to compare the 
categorical data. P-value <0.05  was  considered  significant in the study. 
 
OBSERVATION  AND RESULTS 
 
     49 patients of yellow oleander seed poisoning were enrolled in  the 
study period  from  January 2014 to August 2014. 
Age Incidence : 
   Out of the total 49 patients the number of patients below  age  
20 were 7(15%) and between 20 and 40 were 38 (77.6%) and age above 40 
were 4 (8.2%). The mean age was 27.89± 9.06. In our study incidence of 
poisoning is more  in the age group between 20 and 40. 
Table 2 :  Age Incidence  
 
Age group 
(years) 
Number of 
patients 
Percentage 
    <20 
   20-40 
   >40 
        7 
        38 
        4 
14.2% 
77.6% 
 8.2% 
 
 
 
Fig 13 : Age incidence Pie Chart 
Sex Incidence : 
     Out of the total 49 cases  20 were males and 29 were females . The 
male female ratio was 1:1.6. Percentage of males in this study was 40.8%. 
In men the common age group was 20 -40 years  and  the number of cases 
in this age group was 17 (85%). Number of cases in the age group below 
20 years was 1 (5%) and above 40 was 2(10%). Incidence appears to be  
more in the females  29 (59.2%). In females the common age group was 
between 20-40. The number of patients were 21(72.41%). The number of 
female patients in the age group below 20 was 6(20.6%). The number of 
female patients in the age group above 40 was 2(6.8%). 
    
             Table 3: Sex incidence 
 
 
 
 
 
 
 
 
          
                                                  Fig  14 : Sex  distribution 
 
 
Age group in   
years 
Male 
n(%) 
Female 
n(%) 
<20 1(14.3%) 6(85.7%) 
20-40 17(44.7%) 21(55.3%) 
>40 2(50%) 2(50%) 
Number of seeds consumed: 
     The mean number of seeds consumed was 4.65±2.41. The  range being 
from 1-10. Minimum of 1 seed was consumed by 2 patients and the 
maximum of 10 seeds were consumed by 1 patient. 10 patients had 
consumed  2 seeds (20.4%). 
Table 4: Number of seeds consumed 
No of 
seeds 
consumed 
No of 
patients 
Percentage 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
2 
10 
8 
5 
6 
7 
3 
4 
3 
1 
4.1% 
20.4% 
16.3% 
10.2% 
12.2% 
14.3% 
6.1% 
8.2% 
6.1% 
2% 
 
 
 
Forms  of  consumption : 
     The seeds were taken most commonly in the chewed form. Number of 
patients in chewed form were 22(44.9%). 
Table 5: Forms of seed consumption: 
Form of 
consumption 
Number of 
patients 
Percentage 
Chewed      22     44.9% 
Paste     21    42.9% 
Grounded      6    12.2% 
 
Paste form is considered to be dangerous as glycoside bioavailability is 
increased. 
                      
                                Fig 15 : Form of seed  Pie chart 
 
 Time interval between consumption of poison and admission: 
              The number of patients  admitted  within  6 hours of poisoning 
were 29 (59.2%). The number  of  patients  admitted between 6 -12 hours 
of poisoning were 20(40.8%). 
Table 6: Time interval between consumption and admission 
 
 
 
 
 
 
 
 
 
Gastrointestinal  symptoms: 
 
               Out of the 49 patients 37 patients had GIT symptoms ,12 patients 
had no GIT symptoms . 
 
Time interval 
between poisoning 
and admission 
Number of 
patients 
Percentage 
Less than 6 hours     29 59.2% 
6-12 hours     20 40.8% 
Total patients                           49 
 Table 7: Gastrointestinal symptoms 
GI symptom 
Number of 
patients 
Percentage 
Vomiting 30 61.2% 
Diarrhoea 1 2% 
Vomiting and 
Diarrhoea 
6 12.2% 
No symptoms 12 24.5% 
 
Cardiac symptoms: 
       Out of the 49 patients enrolled in the study only 7 patients had  cardiac 
symptoms .  All the 7 patients developed palpitations. 
 
Table 8: Cardiac Symptoms 
No cardiac 
symptoms 
              42 85.7% 
          Palpitations                 7               14.3% 
 
 
 Mean pulse rate at admission: 
     Out of 49 cases 30 patients had pulse rate in the range of 60-90.Only 19 
patients had pulse rate in the range of 40-60 (38.72%). None of the 
patients in our study had pulse rate less than 40 at admission. The mean 
pulse rate at admission was 69±14. 
Table 9:  Pulse rate at admission 
Pulse rate range Number of patients percentage 
<40 0 0 
40-60 19 38.72% 
60-90 30 61.2% 
 
Incidence  and Type of  ECG  changes: 
      Out of 49 cases , 30 patients (61.2%)  showed  ECG changes. 19 
patients had normal ECG. Various types of ECG changes are shown in 
table 9. Sinus bradycardia is the most common type of ECG  change. The 
other types of ECG changes  are also shown in  the table. 
Table  10: Types of ECG change 
 
 Types of ECG  
change 
  ECG change    
present (n) 
ECG change 
absent (n) 
 Total 
patients 
 Sinus 
bradycardia 
     24       25  
 
 
 
     49 
I-deg.AV block       9       40 
Premature atrial 
contraction 
      5       44 
Tall T waves       3       46 
T wave inversion      4       45 
ST depression      2       47 
Junctional rhytm      1       48 
 
 
 
Fig 16: ECG  showing , Bradycardia and PAC 
  
                            Fig 17:   ECG shows sinus brady cardia 
 
 
Fig 18: ECG shows junctional rhythm with no p waves visible. 
 
              
Fig 19: PAC 
 
           
Fig 20 : Sinus bradycardiaT.his ECG shows sinus brady cardia with Heart rate -49/minute. 
 
           
Fig 21: Bradycardia, 1st degree Heart block 
 
Correlation  between age and ECG changes: 
      Out of 7 patients in the less than  20 age group 5 patients had ECG 
changes (71.4%).  Out of 38 patients in the age group between 20-40 , 22 
patients had ECG changes (57.8%). Out of 4 patients in the age group 
above 40 ,three patients had ECG changes(75%). In our study patients < 
20 years  and > 40 years had  more ECG changes. 
 
 
 
Table 11 :   ECG changes among age groups 
Age group (n) 
years 
Number of patients 
with ECG changes 
Percentage 
      <20 (7)           5       71.4% 
     20-40 (38)         22        57.8% 
     >40 (4)          3        75% 
 
 
                 
  
                         Fig  22: ECG changes among different age groups 
 
 
 
Correlation  of  type of intake with  ECG changes: 
         Maximum  number of ECG changes was seen when seeds were taken 
in paste form. 90% of the patients who had taken the seeds in paste form 
developed ECG changes. 83% of the patients who took the seeds in 
grounded form developed ECG changes. When the seeds were taken as 
such or chewed and eaten only 27% developed ECG changes.  
 
Table 12:  ECG changes-Relation to form of seed taken 
  
 
 
 
     P<0.05 –significant 
                    
 
                              Fig 23:  ECG changes and type of consumption 
Type of intake 
(n-Patients) 
Patients with 
out ECG 
changes 
Patients with 
ECG changes 
 
p-value 
Chewed (22)     16    6 (27.27%)   
     0.01 Ground (6)      1    5 (83.33%) 
Paste (21)     2    19 (90.47%) 
  
 
ECG changes  and  Time of  Hospitalisation  after  poisoning : 
        The patients who presented earlier to the hospital  had less incidence 
of ECG  changes than those presented later to the hospital after poisoning 
.This is proved by the fact that ,the mean  duration of admission to hospital 
after poisoning was 2.9 hrs in those with out ECG changes ,compared to 
6hrs in those with ECG changes . 
 
Table 13: Time after poisoning and ECG change  
 ECG  change  Mean Duration of 
admission after 
poisoning(hrs) 
   P-value 
Present 6.03±2.25  
 0.001 
Absent 2.94±1.43 
   P<0.05 –significant 
 
 
                     Fig 24 : ECG  changes and Time interval from poisoning 
 
 
Correlation between ECG changes  and number of seeds taken: 
       In our study  patients who had ECG changes  had taken significantly 
more number of seeds than those who  did not have ECG change. The 
mean number of seeds in group with ECG change was 5.86  versus 2.73 in 
those with out  ECG change  . 
 
 
 
Table 14: Number of seeds and ECG change 
ECG  change Mean number of 
seeds(n) 
 p-value 
Present 5.86±2.20  
0.001 
Absent 2.73±1.19 
P< 0.05-significant 
           
                          Fig 25: ECG changes and No. of  seeds ingested 
 
 
Correlation between ECG changes and S.K+ 
            In our  study  the  mean serum potassium  levels  was  5.01±0.58 
meq/l (3.5-6.0) . The  mean serum  potassium  was higher  in those with 
ECG  changes  than in those without. 
Table 15:  Serum potassium  and  ECG changes 
ECG change Mean serum 
potassium ( meq/l) 
 p-value 
Present 5.26±0.58  
     0.001 Absent 4.61±0.26 
           p<0.05-significant 
 
 
 
 
      
        
                          Fig 26:  ECG  changes and Serum Potassium 
 
 
 
 
 
 
Total hospitalization days and  ICU stay. 
        In our study the  mean hospitalization stay was   4.10±1.48 days 
(range 2-8 days).  The mean stay was more in those with ECG changes 
than in those with out ECG changes . 7 patients were admitted to the ICU . 
Table 16:  ECG change and total hospitalization 
ECG change Total 
hospitalization(days) 
p-value 
Present 4.73±1.54  
         0.001 Absent 3.10±0.43 
P< 0.05 –significant 
 
Fig 27:  ECG changes and Hospital days 
 
 
 
Correlation between ECG changes and Serum creatinine 
                   The mean serum creatinine in patients with ECG changes was 
0.88±0.08 mg%  versus 0.87±0.07mg%  in those with out ECG changes. 
There was no significant difference between these two groups.(p-0.965) 
Table 17: ECG change and Serum creatinine 
ECG change Mean serum 
creatinine (mg%) 
p-value 
Present 0.88±008  
    0.965 Absent 0.87±0.07 
p< 0.05 –significant 
 
Correlation between Gastrointestinal symptoms and form of seeds 
taken 
          The gastrointestinal symptoms are directly proportional to the  
oleander toxin local action . Oleander taken in paste form  produces more 
GI symptoms than other forms . 
 
 
 
Table 18: GI symptoms and form of seed ingested. 
Form of seed taken GI symptom 
present  n(%) 
GI symptom absent 
n(%) 
Paste   20(95.2%) 1(4.8%) 
Chewed 12(54.5%) 10(45.5%) 
Grounded 5(83.3%) 1(16.7%) 
 
 
DISCUSSION 
       Yellow oleander is a commonly found  plant in our geographical area. 
Poisoning is epidemic in our region and most commonly found in middle 
age group (20-40 yrs-77.6%),as depicted  in the results. This causes 
increased morbidity on the productive work force of  the predominantly 
agricultural community of our district. The findings in our study echoes 
and is consistent with  few other studies published from our country and 
from other countries of the sub-continent. Fonseka et al 48 from Srilanka 
have published their series in 2002 ,with the mean age of 24.8 years and a 
female preponderance. The results of our study was also similar ,with  
mean age of 27.9±9.06 years  and  female preponderance (F: M=1.6:1). 
          As  elaborated in review of literature ,all parts of oleander plant are 
poisonous . Even  smoke from burning the twigs56 can cause inhalational 
toxicity and produce ECG changes. In our study we included patients with 
seed ingestion alone .Oleander seeds are one of the most toxic parts of the 
plant. One of the most debated topic of oleander poisoning is the lethal 
dose of  the seeds and the how the seeds were ingested –the physical form  
it  is taken and its relation to the severity  of symptoms. Regarding the 
lethal dose of the oleander seeds ,we found that  those who had significant 
ECG changes  had significantly (Table-14 ,p-0.001)  higher number of 
seeds ingested than those who did not have ECG change. Our results thus 
show that the lethal dose of oleander seeds may be between 4-8. This is 
consistent with  studies by  Sreeharan et al57 (1985)  and  
Saravanapavananthan et al 21 (1988).  To  the contrary  Eddleston et al  
51,54,55,64 could not find any simple relationship between  the  number of 
seeds ingested and toxic manifestations. The possible explanation for such 
a factor is that  in Eddleston et al’s study there is no mention of  physical 
form of the seed ingested is being shown. Mostly the  seeds might have 
been ingested as a whole rather than taken in a paste or grounded form. In 
our study the  majority of intake is in the paste form ,the most lethal type 
of intake. This  is validated by  our results that ECG changes were found 
in 90% of patients who took oleander in a paste form, compared to 80% in  
grounded form and  27% in chewed form (p-0.01). 
        Yellow oleander is  predominantly cardio-toxic. It can produce  
gastrointestinal and neurologic manifestations. There are no detailed 
studies on these effects as they don’t cause major morbidity. In our study 
we found that  there was no neurologic effects but 75% of  patients had 
gastrointestinal effects , with vomitting as major symptom. Vomiting is 
due to drug  induced gastritis. We also found that in patients whom there 
was gastrointestinal symptoms, there was significant cardiac symptoms. 
The  possible explanation is from the fact that , patient who took the  
oleander paste-most toxic form had both gastrointestinal and cardiac 
symptoms. 
            Cardiac toxicity is the hall mark of oleander seed poisoning. 
Cardiac  glycosides  inhibit Na+/K+ ATPase pump which results in 
increased intracellular Na+  and Ca+  . The  intracellular hypercalcemia 
leads to spontaneous depolarisations and hence increased 
arrhythmogenicity. The rhythm disturbances varies from simple 
bradycardia to complex  bradyarrhythmias . The incidence of various  
bradyarrhythmias   in our study (Table 10 ) is  similar to other studies . 
Results of our study  correlate with  the figures of most recent evidence 
available in literature. Zamani et al58 in 2010  published the incidence of 
various cardiac rhythm disturbances  in yellow oleander poisoning .There 
was 40% incidence of bradyarrhytmias .This is similar to our study in 
which we found out 50%  incidence of bradycardia and 25% incidence of 
heart block. We did not find any case of ventricular fibrillation or ectopics 
. But in literature  the incidence of ventricular ectopics reported is quite 
high. Even in Zamani et al’s  study there is 82% incidence of ventricular 
ectopics and  10%  incidence of ventricular tachycardia. 
             The relationship between  cardiac toxicity and the serum 
biomarkers such as  potassium and creatinine are studied in our study .  
Our results showed that there was no significant difference between  
patients with or with out  ECG changes in respect to serum creatinine . The 
mean serum creatinine in both groups was around  0.8mg%  and the p-
value 0f 0.935 in students ‘t’ test.  This is comparable to studies by 
Zamani et al  and  Lokesh et al. In both of the above studies there was  no 
difference between normal and abnormal ECG groups in respect to the 
mean serum creatinine levels. 
                  In Lokesh et al’ s59 study the mean serum potassium in 
abnormal ECG group was 5.3meq/l  vs 3.5meq/l  in normal ECG group 
with a p-value of 0.01. These results are comparable to our statistics in 
which the mean serum potassium was 5.26 meq/l in abnormal ECG group 
in comparison to 4.6meq/l  in normal ECG group. The p-value was 0.001 
and significant. These findings  emphasize the fact that blockage of 
Na+/K+ ATPase pump leads to the hyperkalemia , and in conjunction with 
the intracellular hypercalcemia  it precipitates the arrhythmias. Zamani et 
al in their  publication published similar results in 2010 that patients with 
ECG changes had significantly higher potassium levels than those with 
normal ECG. 
           Oleander toxicity is time bound and the toxicity increase with  more 
time elapsing after ingestion .This is possibly explained by the fact that , 
more the time seeds in the stomach,more absorption of the toxin and more 
serious the  cardiac effect. The  patients who reached hospital early had 
less morbidity and mortality in various studies . In our study also, earlier 
the admission ,lesser the morbidity .This is proved by the fact that the 
mean duration from poisoning to hospital admission was  6.0±2.0 hrs  in  
patients with cardiotoxicity ,compared to 2.9±1.4 hrs in those with out 
cardiotoxicity (Table-16 , p-0.001). 
     Morbidity in oleander glycoside toxicity is due to the cardiac effects. 
Hence those with electrocardiographic changes needed some form of 
intervention .We used mostly pharmacologic intervention . Drugs used by 
us are atropine and orciprenaline .We did not use digoxin antibodies and 
our hospital didn’t  have facility for cardiac pacing. None of our patients 
however  needed  pacing and there was no hospital mortality.  
     The  total hospital stay was significantly higher in patients who had 
cardiac morbidity .The mean stay was  4.7±1.5 days  in patients with 
abnormal electrocardiograph vs 3.1±0.45 days in patients with normal 
electrocardiograph. This is akin to several studies from other parts of the 
subcontinent. 
         Although the yellow oleander tree is common throughout 
the tropical  and subtropical countries , the use of  oleander seeds for 
suicidal attempts is  common only in  southern India and  parts of Sri 
Lanka. In Malaysia, Indonesia and Thailand though the oleander palnt is 
common ,it is not a popular modality for suicidal use. 
         Even in our country  there are scant reports from north India when 
compared to south India. There are  only occasional reports from central 
and northern India (Modi 198860; Saraswat et al. 199261; Ahlawat etal 62 ). 
Accidental poisonings have been reported from across the world, for 
example the Solomon Islands, Brazil and Australia (Pearn 63 1989). 
However, intentional poisonings in these regions are very uncommon 
(Pearn 1989). 
         Oleander poisoning as a epidemic is seen in South India and Sri 
Lanka. Control of this epidemic must involve both lowering the high 
incidence of deliberate self-harm  and improving the medical management 
of these patients 
(Eddleston et al. 199864). Sociological and psychiatric research should help 
elucidate the cause of the epidemic. However, in the immediate future, 
better medical treatments are urgently required both to relieve the burden 
that oleander poisoning is imposing on the medical services and to reduce 
the case fatality (Eddleston 1997).  
        Polyclonal antidigoxin antibodies (Antman et al. 1990; Kelly & 
Smith 1992)  neutralize the cardiotoxic effects of common oleander leaves 
in dogs (Clark et al. 1991). These antibodies have also been used in 
clinical practice to treat poisoning due to ingestion of oleander leaves 
(Shumaik et al. 1988; Safadi et al. 1995) and bufadienolides (Centers for 
Disease Control & Prevention 1995; Brubacher et al. 199665). The 
response has been mixed and there has been no clinical trial to test their 
efficacy – all reports so far have been of single cases. It is essential that a 
clinical trial of these antibodies is carried out to determine their efficacy. 
The current cost of treating oleander poisoning will then need to be 
evaluated against the cost of the antibodies. If such therapy is judged to be 
economical and enters clinical practice, it will be important to determine 
whether the availability of an antidote for oleander  poisoning influences 
its use for acts of deliberate self-harm. 
 
 
 
 
 
 
 
 
 
 
 
                  
                       SUMMARY AND CONCLUSIONS 
1. Yellow oleander poisoning is common type of suicidal 
poisoning in Thanjavur district. 
2. In our study there was a female preponderance and poisoning 
was more common in age group of 20-40 years. 
3. Chewed form is the most common type of intake followed by 
paste form. 
4. The paste form is the most toxic ,with 90% of patients 
exhibiting gastrointestinal and cardiac manifestations. 
5. 75% of patients had Gastrointestinal symptoms in our study. 
6. No patient had neurological manifestations in our study. 
7. 14% of patients had palpitations  and 61.2% of patients had 
ECG abnormalities 
8. The most common electrocardiographic abnormality is 
Bradycardia (50%) .First degree AV block was seen in 25% of 
patients. 
9. No patient had second degree or third degree heart block. 
10. There was no case of ventricular fibrillation or  tachycardia  
noted in our study. 
11. The mean number of seeds ingested was significantly higher in 
the patients with ECG manifestations. 
12. The lethal dose of oleander seed in our study was  between  4-
8. 
13. The serum potassium was significantly higher in patients with 
ECG changes. 
14. Patients who developed cardiac manifestations had 
significantly  longer hospital stay and ICU stay. 
15. Patients who presented to the hospital early had  less  
incidence of toxic manifestations. 
16. First aid given at home doesn’t bear any correlation to the 
toxic cardiac manifestations. 
17. There was no mortality in our study. All patients had normal 
ECG at discharge. 
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                                              PROFORMA 
             NAME 
            AGE 
            SEX 
            ADDRESS 
   
           IP NO 
          OCCUPATION 
          EDUCATION 
         DATE OF ADMISSION 
         DATE OF DISCHARGE / DATE OF DEATH 
         DETAILS OF POISONING: 
       DATE AND TIME OF POISON 
        NO OF SEEDS 
       COLOUR  
       FORM-    PASTE /GROUNDED/ CHEWED 
      TAKEN -   EMPTY STOMACH/ WITH FOOD /ALCOHOL 
   FIRST AID GIVEN AT HOME-YES/NO 
      TREATED OUTSIDE HOSPITAL-YES/NO 
     TIME INTERVAL BETWEEN ADMISSION AND CONSUMPTION 
     SYMPTOMS 
         GIT-  VOMITTING/ DIARRHOEA/ TINGLING SENSATION IN MOUTH 
         CARDIAC- PALPITATIONS/ SYNCOPE/ DYSPNOEA 
         CNS-HEADACHE / SEIZURES 
    VITALS AT ADMISSION- 
             BP- 
             PR- 
            RR- 
            CVS- 
            RS- 
    INVESTIGATIONS 
        RBS 
        RFT- 
       Serum Potassium 
       ECG  Changes 
             At admission 
             Day 1 
             Day 2 
             Day 3 
         ECHO- 
         
         TOTAL HOSPITALIZATION  DAYS- 
          
        ICU STAY –   
        OUTCOME- 
 
                                                         CONSENT FORM 
 
 
 
          I __________________________________________  hereby give consent to participate in the 
study conducted by DR. G.SUBHA,  post graduate in department of General medicine, Thanjavur 
medical college & Hospital, Thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I also give consent for 
further investigations 
 
 
  Place : 
 Date :            Signature of participant 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name IP No Age sex D O A D O D Time interval from poisoning to admission(HRS)
TAMILSELVAM 25087 27 M 24/5/14 30/5/2014                    8 h 8
SHANTHI 1493270 27 F 28/1/14 30/1/14 5
MALLIKA 1488805 45 F 1/2/2014 5/4/2014 2
SINTHAMANI 37523 18 F 25/7/14 29/7/14 8
SUDHA 36364 23 F 20/7/14 25/7/14 6
LAKSHMI 26743 34 F 31/5/14 2/6/2014 8
ANANDHI 26659 25 F 31/5/14 2/6/2014 7
KOKILA 17461 28 F 11/4/2014 14/4/14 3
DURGADEVI 12936 14 F 16/3/14 18/3/14 1
LAKSHMI 12690 38 F 14/3/14 17/3/14 6
PRIYA 1488670 29 F 2/3/2014 7/3/2014 6
SENTHILJOTHI 31604 22 F 25/6/14 27/6/14 3
PAPPU 22076 30 F 7/5/2014 9/5/2014 2
MYTHILI 148995 28 F 6/3/2014 10/3/2014 4
YASODA 1480847 15 F 4/8/2014 9/8/2014 5
JAYASEELA 1473175 21 F 5/8/2014 7/8/2014 6
RAJATHI 1470823 45 F 22/2/14 28/2/14 5
SASIKALA 1467153 21 F 31/7/14 2/8/2014 2
NADIYA 1458725 29 F 12/5/2014 15/5/14 7
MALINI 20829 16 F 30/4/14 2/5/2014 2
AMARAVATHI 10613 30 F 2/6/2014 4/6/2014 3
KAMALA 8737 24 F 19/2/14 23/2/14 8
JOTHI 6871 18 F 12/2/2014 15/2/14 7
MALLIKA 6251 28 F 5/2/2014 7/2/2014 6
KARTHIGA 41096 21 F 14/8/14 18/8/14 6
RAMESH 37480 30 M 25/7/14 28/7/14 5
KARTHIK 30761 26 M 20/6/14 22/6/14 4
SELVAM 34651 40 M 12/7/2014 20/7/14 12
MURALI 28312 18 M 8/6/2014 10/6/2014 2
RAJA 23666 28 M 16/5/14 22/5/14 6
SATHYAMOORTHI 20214 21 M 27/4/14 2/5/2014 8
PALANISAMY 12998 48 M 17/3/14 18/3/14 2
MOHAN 27851 40 M 3/4/2014 5/4/2014 1
SUGANYA 40247 40 F 10/8/2014 14/8/14 3
RENUGA 48605 25 F 12/8/2014 14/8/14 2
ANANDARAJ 28807 22 M 11/6/2014 15/6/14 6
RAMACHANDRAN 18090 30 M 15/4/14 17/4/14 3
PARVATHY 10847 27 F 3/3/2014 5/3/2014 2
SASIKALA 28776 38 F 6/6/2014 11/6/2014 5
JOHNKARTHIK 34039 25 M 8/7/2014 11/7/2014 5
MURALI 28312 22 M 8/6/2014 10/6/2014 5
KUMAR 28775 56 M 10/6/2014 15/6/14 6
RANJIT 15090 21 M 29/3/14 4/4/2014 10
SANGEETHA 68521 16 F 9/5/2014 11/5/2014 3
PRABHU 19155 27 M 21/4/14 23/4/14 2
MILTON 34946 21 M 13/7/14 15/7/14 5
GOPALAKRISHNAN 38510 30 M 31/7/14 2/8/2014 3
NEELAKANDAN 36787 35 M 21/7/14 26/7/14 8
MURUGAN 17858 25 M 14/6/14 16/4/14 3
Form of plant taken No.of seeds taken Type of intake  Associated intake First Aid GIT symptoms
SEEDS 9 G F Y V     
SEEDS 2 C E Y V
SEEDS 1 C E N NO
SEEDS 7 P F Y V
SEEDS 5 P F N V
SEEDS 5 P E N V,D
SEEDS 3 C F N V
SEEDS 3 C E Y V,D
SEEDS 2 C E N V,D
SEEDS 5 G F Y V
SEEDS 8 P F Y V,D
SEEDS 3 C F Y NO
SEEDS 2 C E N V
SEEDS 4 C E Y V
SEEDS 6 P E Y V
SEEDS 3 P F Y V
SEEDS 5 P F N V
SEEDS 2 C E N V
SEEDS 4 P E N V
SEEDS 2 C F Y V
SEEDS 4 G F Y V
SEEDS 9 P F N V,D
SEEDS 6 P F N V
SEEDS 2 C E Y NO
SEEDS 6 P E N D
SEEDS 7 P E N V
SEEDS 3 C F Y NO
SEEDS 8 P A N V
SEEDS 1 C E Y V
SEEDS 6 P F N V
SEEDS 9 P A N V,D
SEEDS 3 C E Y NO
SEEDS 2 C E N NO
SEEDS 3 G F N NO
SEEDS 2 C F Y NO
SEEDS 8 P F N V
SEEDS 2 C E Y V
SEEDS 3 C E Y V
SEEDS 6 G E Y V
SEEDS 4 P E N V
SEEDS 7 G E Y V
SEEDS 5 C A Y V
SEEDS 10 P A N V
SEEDS 2 C E Y NO
SEEDS 6 C A N NO
SEEDS 8 P A N NO
SEEDS 4 C A N NO
SEEDS 6 P A N V
SEEDS 5 P A N V
  cardiac symptoms CNS symptoms Pulse rate ECG changes Type of ECG Change  SB
PALPITATIONS NO 50 YES SB,1DAVB,PAC YES
NO NO 80 NO NO
NO NO 90 NO NO
NO NO 80 YES SB YES
NO NO 70 YES SB,1DAVB YES
NO NO 78 YES SB,PAC YES
NO NO 56 YES SB YES
NO NO 80 NO NO
NO NO 70 NO NO
NO NO 70 YES SB YES
NO NO 50 YES SB,1DAVB,PAC YES
NO NO 88 NO NO
NO NO 88 NO NO
NO NO 60 YES SB,1DAVB YES
NO NO 59 YES SB YES
NO NO 85 NO NO
NO NO 58 YES SB,1DAVB YES
NO NO 87 NO NO
NO NO 65 YES STD NO
NO NO 87 YES TI NO
NO NO 50 YES SB YES
PALPITATIONS NO 49 YES SB,1DAVB,TI YES
NO NO 56 YES SB,STD YES
NO NO 80 NO NO
NO NO 50 YES SB,PAC YES
PALPITATIONS NO 56 YES SB YES
NO NO 80 NO NO
PALPITATIONS NO 42 YES SB,JR YES
NO NO 76 YES TI NO
NO NO 60 YES SB,PAC,TALL T YES
PALPITATIONS NO 42 YES SB,1DAVB YES
NO NO 80 YES STD NO
NO NO 78 NO NO
NO NO 80 NO NO
NO NO 89 NO NO
PALPITATIONS NO 48 YES SB,1DAVB YES
NO NO 78 NO NO
NO NO 79 NO NO
NO NO 60 YES SB YES
PALPITATIONS NO 60 YES SB,1DAVB YES
NO NO 80 YES SB YES
NO NO 67 YES TALL T NO
NO NO 50 YES SB,TALL T YES
NO NO 78 NO NO
NO NO 87 NO NO
NO NO 56 YES SB YES
NO NO 78 NO NO
NO NO 65 YES TI NO
NO NO 78 NO NO
1DAVB PAC TI STD
YES YES NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
YES NO NO NO
NO YES NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
YES YES NO NO
NO NO NO NO
NO NO NO NO
YES NO NO NO
NO NO NO NO
NO NO NO NO
YES NO NO NO
NO NO NO NO
NO NO NO YES
NO NO YES NO
NO NO NO NO
YES NO YES NO
NO NO NO NO
NO NO NO NO
NO YES NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO YES NO
NO YES NO NO
YES NO NO NO
NO NO NO YES
NO NO NO NO
NO NO NO NO
NO NO NO NO
YES NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
YES NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO NO NO
NO NO YES NO
NO NO NO NO
TALL T JR ECG I ECG II ECG III ECG IV
NO NO 1DAVB,SB,PAC SB,1DAVB SB,1DAVB SB
NO NO N N N N
NO NO N N N N
NO NO N SB SB SB
NO NO N 1DAVB SB SB
NO NO N SB SB PAC
NO NO SB SB SB N
NO NO N N N N
NO NO N N N N
NO NO N SB SB N
NO NO SB,1DAVB SB,1DAVB SB PAC
NO NO N N N N
NO NO N N N N
NO NO SB SB SB,1DAVB 1DAVB
NO NO SB SB SB N
NO NO N N N N
NO NO SB SB SB,1DAVB N
NO NO N N N N
NO NO N N STD TI
NO NO N N N TI
NO NO SB SB SB N
NO NO SB,1DAVB SB,1DAVB SB TI
NO NO SB SB SB STD
NO NO N N N N
NO NO SB,PAC SB N N
NO NO SB SB SB N
NO NO N N N N
NO YES SB SB SB JR
NO NO N N N TI
YES NO SB SB ,TALL T SB, TALL T SB
NO NO SB,1DAVB SB,1DAVB SB SB
NO NO N N N STD
NO NO N N N N
NO NO N N N N
NO NO N N N N
NO NO SB ,1DAVB SB,1DAVB SB SB
NO NO N N N N
NO NO N N N N
NO NO N SB SB SB
NO NO SB,1DAVB SB,1DAVB SB SB
NO NO SB SB,T I T I N
YES NO TALL T TALL T N N
YES NO SB,TALL T SB,TALL T SB SB
NO NO N N N N
NO NO N N N N
NO NO SB SB N N
NO NO N N N N
NO NO TI SB N N
NO NO N N N N
ECG V          ECG VI SR.C S.K+ RBS ECHO  ICU stay Total hospital days
N                        N 0.9 5.6 80 N NO 6
N                        N 0.8 5 70 N NO 3
N                        N 0.9 4.5 89 N NO 3
N                        N 1 5 90 N NO 5
SB                       N 0.9 5.7 75 N NO 6
N                        N 0.8 5.5 67 N NO 3
N                        N 0.9 5 78 N NO 3
N                        N 0.8 4.7 87 N NO 3
N                        N 0.8 4.4 76 N NO 3
N N 0.9 4.9 88 N NO 4
SB                       N 0.8 5.7 90 N YES 6
N                        N 0.9 4 98 N NO 3
N                        N 0.9 4.6 78 N NO 3
N                        N 1 5.5 67 N NO 5
N                        N 0.8 4.9 76 N NO 6
N                        N 0.8 5 74 N NO 3
SB                       N 0.9 5.6 75 N NO 7
N                        N 0.8 4.3 78 N NO 3
N                        N 0.9 5 96 N NO 3
N                        N 0.8 4.8 72 N NO 3
N                        N 0.8 5 83 N NO 3
N                        N 0.9 5.7 78 N YES 5
N                        N 0.8 5 87 N NO 5
N                        N 0.8 4.6 87 N NO 3
N N 0.9 5.5 97 N NO 5
 N N 0.9 5.8 95 N NO 4
N N 1 4.8 76 N NO 3
N N 1 5.7 78 N YES 8
N N 0.8 4.4 98 N NO 3
PAC N 0.9 6 74 N YES 7
N N 0.7 5.9 78 N YES 7
N N 1 4.7 65 N NO 2
N N 0.8 4.8 78 N NO 3
N N 0.9 4.8 89 N NO 5
N N 1 4.8 74 N NO 3
N N 1.1 6 76 N YES 5
N N 0.9 5 86 N NO 3
N N 1 4.6 76 N NO 3
N N 0.8 3.5 67 N NO 4
SB                       N 0.9 6 68 N NO 4
N N 0.8 4.5 87 N NO 3
N N 0.9 4.6 87 N NO 5
SB                       N 0.9 5.8 89 N YES 7
N N 1 4.3 90 N NO 3
N N 0.9 4.5 98 N NO 3
N N 0.8 5 89 N NO 3
N N 0.9 4.5 67 N NO 3
N N 0.9 5.7 84 N NO 5
N N 0.8 4.5 84 N NO 3
 Outcome
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
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G
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G
G
G
G
G
G
G
G
G
G
G
G
G
G
